{
    "nctId": "NCT02760251",
    "officialTitle": "Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim",
    "inclusionCriteria": "* Informed consent as documented by signature (see informed consent form)\n* Primary ITP according to the definition of Rodeghiero et al. (52) and a platelet count of \\<30x109/l\n* Age range: 18-45 years\n* Previously treated patients, with failure or intolerance to first-line therapy, or relapse after first-line therapy, i.e. corticosteroids, intravenous immunoglobulin (IVIG), or anti-D immunoglobulins\n* Must have minimum age of 18 Years\n* Must have maximum age of 45 Years",
    "exclusionCriteria": "* Adults older than 45 and children younger than 18 years\n* Platelet count higher than 30x109/l at time of screening\n* Suspicion of secondary ITP\n* Positive family history for ITP\n* Presence or history of autoimmune disease as judged by the investigator\n* Hepatosplenomegaly\n* Presence or history of relevant hepatic disease as judged by the investigator\n* Presence or history of thromboembolic disease as judged by the investigator\n* Patients with splenectomy\n* Women who are pregnant or breast feeding\n* Intention to become pregnant during the course of the study\n* Lack of safe double contraception (see 7.1)\n* Any vaccination 2 weeks prior start of the study\n* Drugs with a known impact on the immune system or on platelet function must be recorded and an exclusion of the study should be discussed with the study center\n* Known or suspected non-compliance, drug or alcohol abuse\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia of the study subject\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Previous enrolment into the current study\n* Previous treatment with romiplostim or eltrombopag\n* Hypersensitivity to the active substance or to any of the excipients or to E. coli derived proteins\n* Enrolment of the investigator, his/her family members, employees and other dependent persons"
}